Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02278133 |
Recruitment Status :
Completed
First Posted : October 29, 2014
Last Update Posted : October 9, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to assess the safety and anti-tumor activity of the triple combination of WNT974, LGX818 and cetuximab in BRAFV600-mutant mCRC with RNF43 mutations or RSPO fusions.
The design of this study is based upon the translational and pre-clinical data that suggest that Wnt pathway signals, increased due to RNF43 mutations or RSPO fusions, cooperate with the EGFR and BRAF signals to maintain the growth of BRAFV600 CRCs. Inhibition of these signals with the triple combination of WNT974, LGX818 and cetuximab may result in anti-tumor activity.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Colorectal Cancer | Drug: WNT974 Drug: LGX818 Biological: Cetuximab | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase Ib/II Multi-center, Open Label, Dose Escalation Study of WNT974, LGX818 and Cetuximab in Patients With BRAFV600-mutant KRAS Wild-type Metastatic Colorectal Cancer Harboring Wnt Pathway Mutations |
Study Start Date : | December 2014 |
Actual Primary Completion Date : | May 31, 2016 |
Actual Study Completion Date : | June 23, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: WNT974, LGX818 and cetuximab combo
Phase l: Dose Escalation phase; Phase ll: SIngle group assessing the triple combination of WNT974, LGX818 and cetuximab
|
Drug: WNT974 Drug: LGX818 Biological: Cetuximab |
- Incidence of Dose Limiting Toxicities and exposure (AUC C1D15) to WNT974 and LGX818 (phase lb) [ Time Frame: 12 months ]Phase Ib: To estimate the MTD(s) and/or RP2D(s) of the triple combination of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant, KRAS wild-type (WT) mCRC harboring upstream Wnt pathway mutations.
- Overall response rate in phase II [ Time Frame: 30 months ]Phase II: To estimate the preliminary anti-tumor activity of the RP2D(s) of the combination of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant metastatic CRC harboring upstream Wnt pathway mutations
- Overall response rate (ORR) (phase lb) [ Time Frame: 36 months ]To assess additional parameters of clinical activity of WNT974 in combination with LGX818 and cetuximab in BRAFV600-mutant mCRC with evidence of upstream Wnt pathway activation.
- Overall survival (OS) (phase lb/ll) [ Time Frame: 36 months ]To assess additional parameters of clinical activity of WNT974 in combination with LGX818 and cetuximab in BRAFV600-mutant mCRC with evidence of upstream Wnt pathway activation.
- Duration of response (DOR) (phase lb/ll) [ Time Frame: 36 months ]To assess additional parameters of clinical activity of WNT974 in combination with LGX818 and cetuximab in BRAFV600-mutant mCRC with evidence of upstream Wnt pathway activation.
- Time to response (TTR) (phase lb/ll) [ Time Frame: 36 months ]To assess additional parameters of clinical activity of WNT974 in combination with LGX818 and cetuximab in BRAFV600-mutant mCRC with evidence of upstream Wnt pathway activation.
- Progression free survival (PFS) (phase lb/ll) [ Time Frame: 36 months ]To assess additional parameters of clinical activity of WNT974 in combination with LGX818 and cetuximab in BRAFV600-mutant mCRC with evidence of upstream Wnt pathway activation.
- Disease control rate (DCR) (phase lb/ll) [ Time Frame: 36 months ]To assess additional parameters of clinical activity of WNT974 in combination with LGX818 and cetuximab in BRAFV600-mutant mCRC with evidence of upstream Wnt pathway activation.
- Plasma concentration of WNT974, LHA333, LGX818 (phase lb/ll) [ Time Frame: 30 months ]To characterize the pharmacokinetics (PK) of WNT974, its pharmacologically active metabolite LHA333, and LGX818 when used in combination therapy with cetuximab
- Number of participants with Adverse Events as a measure of safety and tolerability (phase lb/ll) [ Time Frame: 30 months ]To characterize the safety and tolerability of WNT974 in combination with LGX818 and cetuximab in patients with BRAFV600-mutant mCRC with evidence of upstream Wnt pathway activation
- Number of participants with Serious Adverse Events as a measure of safety and tolerability(phase lb/ll) [ Time Frame: 30 months ]To characterize the safety and tolerability of WNT974 in combination with LGX818 and cetuximab in patients with BRAFV600-mutant mCRC with evidence of upstream Wnt pathway activation
- Biomarker activations for WNT and RTK-MAPK pathways (phase Ib/II) [ Time Frame: 32 months ]Phase Ib/II: To assess the pharmacodynamic effect of WNT974, LGX818 in combination with cetuximab and a potential relationship with clinical outcome
- Number of participants with dose interruptions and dose reductions (phase Ib/II) [ Time Frame: 30 months ]To characterize the safety and tolerability of WNT974 in combination with LGX818 and cetuximab in patients with BRAFV600-mutant mCRC with evidence of upstream Wnt pathway activation

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female aged ≥ 18 years
- Histological or cytological confirmed metastatic colorectal cancer
- Written documentation of KRAS wild-type status and BRAFV600-mutation with RNF43 mutation and/or RSPO fusion
- Progression of disease after at least one prior standard of care regimen or intolerant to irinotecan based regimens
- Availability of a representative tumor specimen (primary or metastatic, archival or newly obtained)
- Measurable disease as per RECIST v1.1
- Eastern cooperative oncology group (ECOG) performance status ≤ 2
Exclusion Criteria:
- Phase II only: Prior treatment with RAF inhibitors, Wnt pathway inhibitors, cetuximab, panitumumab, and/or other EGFR inhibitors
- Symptomatic brain metastasis. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid and anti-epileptic therapy are allowed to enroll
- Current treatment with medications or consuming foods that are strong inhibitors or inducers of CYP3A4/5 or herbal medications and that cannot be discontinued at least one week prior to the start of treatment.
- Symptomatic or untreated leptomeningeal disease
- Acute or chronic pancreatitis
- Clinically significant cardiac disease
-
Patients with any of the following laboratory values at Screening/baseline
- Absolute neutrophil count (ANC) <1,500/mm3
- Platelets < 100,000/mm3
- Hemoglobin < 9.0 g/dL
- Serum creatinine >1.5 x ULN or calculated or directly measured CrCl < 50% lower limit of normal
- Serum total bilirubin >1.5 x ULN
- AST/SGOT and/or ALT/SGPT > 2.5 x ULN, (> 5 x ULN if liver metastases present)
- Patients with impaired hepatic function as defined by Childs-Pugh class B or C
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral WNT974/LGX818
Other protocol-defined inclusion/exclusion criteria may apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02278133
United States, New York | |
Memorial Sloan-Kettering Cancer Center (MSKCC) MSKCC (3) | |
New York, New York, United States, 10065 | |
United States, South Carolina | |
Medical University of South Carolina Oncology Dept | |
Charleston, South Carolina, United States, 29425 | |
United States, Texas | |
University of Texas/MD Anderson Cancer Center Onc. Dept, | |
Houston, Texas, United States, 77030-4009 | |
United States, Wisconsin | |
University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc | |
Madison, Wisconsin, United States, 53792-6164 | |
Australia, Victoria | |
Array BioPharma Investigative Site | |
Parkville, Victoria, Australia, 3050 | |
Belgium | |
Array BioPharma Investigative Site | |
Leuven, Belgium, 3000 | |
Canada, Alberta | |
Array BioPharma Investigative Site | |
Edmonton, Alberta, Canada, T6G 1Z2 | |
Canada, British Columbia | |
Array BioPharma Investigative Site | |
Vancouver, British Columbia, Canada, V5Z 4E6 | |
Canada, Ontario | |
Array BioPharma Investigative Site | |
Toronto, Ontario, Canada, M5G 2M9 | |
France | |
Array BioPharma Investigative Site | |
Bordeaux, France, 33076 | |
Array BioPharma Investigative Site | |
Marseille, France, 13273 | |
Israel | |
Array BioPharma Investigative Site | |
Tel-Aviv, Israel, 6423906 | |
Italy | |
Array BioPharma Investigative Site | |
Milano, MI, Italy, 20133 | |
Netherlands | |
Array BioPharma Investigative Site | |
Amsterdam, Netherlands, 1066 CX | |
Singapore | |
Array BioPharma Investigative Site | |
Singapore, Singapore, 169610 | |
Spain | |
Array BioPharma Investigative Site | |
Barcelona, Catalunya, Spain, 08035 | |
Array BioPharma Investigative Site | |
Hospitalet de LLobregat, Catalunya, Spain, 08907 | |
Array BioPharma Investigative Site | |
Madrid, Spain, 28041 | |
Array BioPharma Investigative Site | |
Madrid, Spain, 28050 |
Study Director: | Clinical Trial Call Center | Array BioPharma, Inc. |
Responsible Party: | Array BioPharma |
ClinicalTrials.gov Identifier: | NCT02278133 |
Other Study ID Numbers: |
CWNT974X2102C |
First Posted: | October 29, 2014 Key Record Dates |
Last Update Posted: | October 9, 2017 |
Last Verified: | October 2017 |
metastatic, Colorectal cancer, WNT974, LGX818, cetuximab, |
BRAF-mutant, mCRC, BRAFV600-mutant, KRAS |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases |
Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Cetuximab Antineoplastic Agents, Immunological Antineoplastic Agents |